Cyclosporin A in perforating keratoplasty.
Systemically administered cyclosporin A offers three advantages for the management of high risk keratoplasties. First, its immunomodulating action reduces the risk of immune complications. Second, it can be used in cases where no topical steroids can be applied. Third, it may exert an extra beneficial effect on underlying disadvantageous immune disorders like endogenous eczema. We present some of the currently available core data on 12/1986 through 2/1993.
Sundmacher
R
R
University Eye Hospital, Heinrich-Heine-University Düsseldorf, Germany.
Reinhard
T
T
D016572:Cyclosporine / Q000008:administration & dosage*; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015948:Keratoplasty, Penetrating; D012307:Risk Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine